Cyclic Materials Announces USD $25M Investment to Establish Centre of Excellence for Rare Earth Recycling in Kingston, Ontario
Cyclic Materials, the advanced recycling company building a circular supply chain for rare earth elements (REEs), today announced a USD $25 million investment to launch North America’s first Centre of Excellence for rare earth recycling in Kingston, Ontario, which will result in 45 new skilled jobs in the region.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250611186175/en/
Cyclic Materials' Centre for Excellence located in Kingston, Ontario
Spanning over 140,000 square feet, the first-of-its-kind facility will serve as Cyclic’s industrial and innovation backbone, combining full-scale commercial processing and cutting-edge research and development (R&D) to address one of the world’s most pressing supply chain challenges: the resilient sourcing of rare earth elements for use in permanent magnets.
A Strategic Facility Serving a Circular Future
The Kingston Centre of Excellence will house Cyclic Materials’ first commercial “Hub” processing unit, leveraging the company's proprietary REEPureSM technology. The facility is designed to convert 500 tonnes of magnet-rich feedstock annually into recycled Mixed Rare Earth Oxide (rMREO)—a product containing crucial components for permanent magnets used in EV motors, wind turbines, and consumer electronics such as Neodymium, Praseodymium, Terbium, and Dysprosium. Feedstock for this facility will be sourced from both Cyclic’s Arizona-based “Spoke”, where end-of-life products will be processed, as well as a growing network of partners supplying magnet scrap from production.
With operations set to begin in Q1 2026, rMREO from this facility will supply key partners within the magnet value chain, like Solvay, with whom Cyclic Materials signed an offtake agreement in 2024, providing a secondary resource of critical rare earth elements.
The site will also house a state-of-the-art R&D center, including advanced labs and a mini-Spoke line, to accelerate process optimization and scale next-generation technologies across the rare earth value chain.
Breaking Global Dependency with Local Innovation
Today, less than 1% of rare earth elements are recycled, and global supply chains remain highly sensitive to growing geopolitical tensions and supply concentration. Cyclic Materials’ proprietary MagCycle℠ and REEPure℠ technologies recover REEs from end-of-life products such as EVs, wind turbines, and data center hard drives—delivering a low-footprint, circular alternative to mining and a fast track to domestic supply security.
“With this Centre of Excellence, we’re advancing our core mission: to secure the most critical elements of the energy transition through circular innovation,” said Ahmad Ghahreman, CEO of Cyclic Materials. “Kingston is where Cyclic began—and now it’s where we’re anchoring our commercial future.”
Kingston: The Cornerstone for the Next Generation of Cleantech
Kingston has played a foundational role in the company’s success—home to its commercial demonstration facilities and a deep bench of collaborators in research, engineering, and cleantech.
The Centre of Excellence will build on robust partnerships with Queen’s University, Kingston Process Metallurgy (KPM), RXN Hub, and Impact Chemistry, as well as support from national innovation programs including CMRDD (Critical Minerals Research, Development and Demonstration) from Natural Resources Canada, Sustainable Development Technology Canada (SDTC), and the National Research Council’s Industrial Research Assistance Program (IRAP).
The facility is expected to create over 45 highly qualified new jobs, with more than 20 hires already onboard. Recruitment has already started with key roles for plant operators, process technicians, and innovation staff.
"We are thrilled to see Cyclic Materials' significant investment to establish their Centre of Excellence and Hub in Kingston, Ontario. This announcement not only creates high-quality jobs in the community but is a reflection of the expertise, talent, and supportive ecosystem Kingston has to offer companies,” said Shelley Hirstwood, Director of Business Development at Kingston Economic Development Corporation. “We are proud to support Cyclic Materials' efforts to create a circular supply chain addressing Canada's critical minerals and rare earth elements."
Scaling a North American Rare Earth Recycling Network
This investment marks a pivotal step in Cyclic Materials’ broader plan to scale its rare earth recycling infrastructure across North America and Europe.
With strategic alliances including Solvay, Glencore, Lime, and Sims Lifecycle Solutions, the company is building a resilient, sustainable, and circular ecosystem for rare earth magnets—supporting the electrification of industries and the secure supply of critical materials.
About Cyclic Materials
Cyclic Materials, founded in 2021, is a cleantech company building a circular supply chain for rare earth elements (REEs) and other critical materials essential to the clean energy transition. Its innovative technology transforms end-of-life products into valuable raw materials used in EVs, wind turbines, and electronics. In 2023, the company launched a commercial demo facility using its MagCycle℠ process to recover rare earth magnets. In 2024, it opened a second facility in Kingston, Ontario, producing Mixed Rare Earth Oxide via its REEPure℠ hydrometallurgical process. With demand for REE-based magnets surging, Cyclic Materials is scaling globally across North America, Europe, and Asia. Mesa, Arizona, is its first U.S. location. In recognition of its pioneering work, it was named the #8 Most Innovative company in North America by Fast Company in 2025. Learn more at cyclicmaterials.earth.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250611186175/en/
Contacts
Media
Jacquie Kane
cyclicmaterials@antennagroup.com
978-764-7840
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press Release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press Release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom